HUNAN HANSEN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.23 CNY | -0.19% |
|
+2.75% | -22.86% |
| 2023 | Hansen Pharmaceutical Gets Nod to Amend Information for Isoniazid Tablets | MT |
| 2023 | Hunan Hansen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 892M 123M | Sales 2022 | 916M 126M | Capitalization | 3.08B 426M |
|---|---|---|---|---|---|
| Net income 2021 | 135M 18.63M | Net income 2022 | 168M 23.19M | EV / Sales 2021 | 3.57 x |
| Net cash position 2021 | 7.76M 1.07M | Net cash position 2022 | 161M 22.23M | EV / Sales 2022 | 3.19 x |
| P/E ratio 2021 |
23.7
x | P/E ratio 2022 |
18.4
x | Employees | 1,533 |
| Yield 2021 * |
-
| Yield 2022 |
4.89% | Free-Float | 46.71% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.19% | ||
| 1 week | +2.75% | ||
| Current month | -5.08% | ||
| 1 month | -2.43% | ||
| 3 months | -12.83% | ||
| 6 months | -20.03% | ||
| Current year | -22.86% |
1 week
4.97
5.56
1 month
4.805.86
Current year
4.087.07
1 year
4.087.38
3 years
4.089.58
5 years
4.0813.50
10 years
4.0823.82
| Managers | Title | Age | Since |
|---|---|---|---|
Zheng Qing Liu
CEO | Chief Executive Officer | 60 | 08-01-19 |
Jiang Hong Dai
DFI | Director of Finance/CFO | 54 | 20-05-24 |
Sai Cheng Liu
CHM | Chairman | 62 | 20-05-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zheng Qing Liu
CEO | Chief Executive Officer | 60 | 08-01-19 |
Ping Zhan
BRD | Director/Board Member | 59 | 20-05-18 |
Ren Hui Fu
BRD | Director/Board Member | 54 | 08-01-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 5.23 | -0.19% | 8 248 491 |
| 24-04-25 | 5.24 | +1.35% | 8,089,907 |
| 24-04-24 | 5.17 | 0.00% | 9,634,195 |
| 24-04-23 | 5.17 | -0.96% | 12,355,370 |
| 24-04-22 | 5.22 | +3.37% | 17,214,210 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of traditional Chinese medicine preparations, chemical medicine and medical preparations. The Companyâs main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The Company mainly distributes its products in domestic markets.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -22.86% | 364M | |
| +26.12% | 653B | |
| +27.00% | 556B | |
| -6.59% | 354B | |
| +20.34% | 331B | |
| +2.79% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.30% | 144B |
- Stock Market
- Equities
- 002412 Stock
